Last edition
News about "BioXcel Therapeutics"
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
BioXcel Therapeutics | 02/04/2026 | By News Bureau | 102
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
BioXcel Therapeutics | 02/04/2026 | By News Bureau | 102
BioXcel to develop drugs in oncology
BioXcel shapes entirely claimed auxiliary OnkosXcel to foster prescriptions centered in oncology
BioXcel Therapeutics | 21/04/2022 | By Sudeep Soparkar | 836
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy